市場調查報告書
商品編碼
1468618
退伍軍人症桿菌檢測市場報告(按應用(水檢測、IVD 檢測)、最終用戶(診斷實驗室、醫院和診所等)和地區)2024-2032 年Legionella Testing Market Report by Application (Water Testing, IVD Testing), End User (Diagnostic Laboratories, Hospital and Clinics, and Others), and Region 2024-2032 |
2023年,全球IMARC Group菌檢測市場規模達3.085億美元。
退伍軍人症桿菌是一種影響下呼吸道的感染,可導致嚴重肺炎、龐蒂亞克熱和類似流感症狀的疾病。其測試有助於識別血液、尿液和痰中是否有細菌或抗原。目前,診斷退伍軍人菌症的檢測方法有多種,包括尿液抗原、配對血清學、聚合酶連鎖反應(PCR)、直接螢光抗體(DFA)染色、下呼吸道分泌物培養等。根據檢測結果,通常對患者給予大環內酯類、喹諾酮類、四環素、強力黴素、米諾環素、甲氧芐啶等抗生素治療。
50 歲以上的成年人更容易感染 退伍軍人症桿菌。因此,全球老年人口的增加是正面影響市場的主要因素之一。此外,越來越多的吸菸者和患有癌症、糖尿病、腎臟病、人類免疫缺陷病毒(HIV)或其他慢性疾病的人面臨感染和住院的風險。由於 退伍軍人症桿菌的死亡率很高,對其有效的診斷測試和治療的需求不斷增加。除此之外,引起 退伍軍人症桿菌的細菌主要存在於不同的自然和人工水生環境中,例如冷卻水塔、呼吸治療設備、噴泉、噴霧裝置、水療池以及飯店、家庭和工廠的供水系統。因此,許多國家的衛生機構正在製定有效的水安全計畫(WSP),以盡量減少 退伍軍人症桿菌在水中的擴散。這反過來又增加了在工作場所進行 退伍軍人症桿菌測試以遵守立法的需求。此外,最近針對成人社區型肺炎患者的診斷和治療策略的臨床試驗也促進了市場的成長。
The global legionella testing market size reached US$ 308.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 578.0 Million by 2032, exhibiting a growth rate (CAGR) of 7% during 2024-2032.
Legionella is an infection affecting the lower respiratory tract, which can lead to severe pneumonia, Pontiac fever, and illness with flu-like symptoms. Its testing helps to identify the existence of bacteria or antigens in blood, urine, and sputum. Presently, various testing methods are available to diagnose Legionella disease, including urinary antigen, paired serology, Polymerase Chain Reaction (PCR), Direct Fluorescent Antibody (DFA) stain, and culture of lower respiratory secretions. As per the testing results, macrolides, quinolones, tetracycline, doxycycline, minocycline, trimethoprim and other antibiotic treatments are usually administered to patients.
Adults over the age of 50 years are more likely to develop Legionella. Consequently, the increasing geriatric population worldwide represents one of the major factors influencing the market positively. Moreover, the rising number of individuals who smoke and have cancer, diabetes, kidney disease, human immunodeficiency virus (HIV), or other chronic illnesses are at the risk of infection and hospitalization. Since the mortality rate of Legionella is high, there is an increase in the demand for its effective diagnostic tests and treatments. Besides this, Legionella-causing bacteria are majorly found in different natural and artificial aquatic environments, such as cooling towers, respiratory therapy equipment, fountains, misting devices, spa pools, and water systems in hotels, homes, and factories. As a result, health agencies of numerous countries are developing an effective water safety plan (WSP) to minimize the proliferation of Legionella in the water. This, in turn, is escalating the demand for Legionella testing in workplace buildings to comply with the legislation. Furthermore, recent clinical trials on diagnostic and treatment strategies for adult patients with community-acquired pneumonia are contributing to the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global legionella testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application and end user.
Water Testing
Microbial Culture
DFA Stain
PCR
Others
IVD Testing
Blood Culture
Urine Antigen Test
DFA Stain
PCR
Others
Diagnostic Laboratories
Hospital and Clinics
Others
Europe
Italy
Germany
France
Spain
United Kingdom
Russia
Others
North America
United States
Canada
Asia Pacific
China
Japan
Australia
South Korea
Indonesia
Singapore
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Becton, Dickinson and Company, BioMerieux SA, Bio-Rad Laboratories Inc, Eiken Chemical Co. Ltd, Quidel Corporation, Takara Bio Inc., and Thermo Fisher Scientific Inc.